3 recruiting, 1 completed, 1 not yet recruiting, 1 unknown. 3 Phase 1, 2 Phase 3, 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 2, Completed 1 |
| Phase 3 | 2 | Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
| Phase 4 | 1 | Unknown 1 |
Follow Higher-Risk Myelodysplastic Syndrome: new trials by email Literature Review of Higher-Risk Myelodysplastic Syndrome trials Research Report on Higher-Risk Myelodysplastic Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS) GEN3018 - R/R AML, R/R HR-MDS | Phase 1 | Recruiting | Genmab | 78 | 2026-02-16 | 2026-10-27 |
| AZA+Lus VS AZA Monotherapy in HR-MDS Azacitidine (AZA), Luspatercept - Higher-risk Myelodysplastic Syndrome | Phase 3 | Not yet recruiting | Peking Union Medical College Hospital | 86 | 2025-04-01 | 2025-04-15 |
| Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4). Lisaftoclax (APG-2575), Azacitidine Injection, Placebo - Higher-risk Myelodysplastic Syndrome | Phase 3 | Recruiting | Ascentage Pharma Group Inc. | 490 | 2025-01-22 | 2026-10-13 |
| Study of 3D189 in Patients With Hematologic Malignancies 3D189 - Acute Leukemia, Multiple Myeloma | Phase 1 | Completed | 3D Medicines | 16 | 2022-08-01 | 2026-09-09 |
| Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies CCS1477, Pomalidomide, Dexamethasone - Haematological Malignancy, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | CellCentric Ltd. | 250 | 2019-08-09 | 2026-06-24 |
| Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation decitabine - Higher-risk Myelodysplastic Syndrome, Relapsed /Refractory Acute Myeloid Leukemia | Phase 4 | Unknown | The First Affiliated Hospital of Soochow University | 30 | 2009-09-01 | 2013-03-12 |
Leukemia, Myeloid, Acute (3) · Lymphoma, Non-Hodgkin (2) · Multiple Myeloma (2) · Hematologic Neoplasms (1) · Lymphoma, T-Cell, Peripheral (1) · Myelodysplastic Syndromes (1)
Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Leukemia (3) · Leukemia, Myeloid (3) · Blood Protein Disorders (2) · Cardiovascular Diseases (2) · Hemorrhagic Disorders (2) · Hemostatic Disorders (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoma (2) · Lymphoproliferative Disorders (2)
Azacitidine (3) · Bortezomib (1) · CCS1477 (1) · Decitabine (1) · Dexamethasone (1) · Lenalidomide (1) · Lisaftoclax (1) · daratumumab (1) · ixazomib (1) · luspatercept (1) · pomalidomide (1) · venetoclax (1)
3D Medicines (1) · Ascentage Pharma Group Inc. (1) · CellCentric Ltd. (1) · Genmab (1) · Peking Union Medical College Hospital (1) · The First Affiliated Hospital of Soochow University (1)
Spain (3) · China (2) · France (2) · Italy (2) · Sweden (2) · United Kingdom (2) · United States (2) · Australia (1) · Belgium (1) · Bulgaria (1) · Canada (1) · Czechia (1) · Denmark (1) · Finland (1) · Germany (1)
Guillermo Garcia-Manero, M.D. (1) · Tim Somervaille (1) · Xiaojun Huang, M.D., Ph.D. (1)
2025 (1)